Nasdaq Stock Market LLC filed a Form 25 on November 17, 2026, notifying the SEC of the removal of Pacira BioSciences, Inc. common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

Key Highlights

  • Issuer: Pacira BioSciences, Inc., listed at 5 Sylvan Way, Suite 125, Parsippany, New Jersey 07054
  • Security affected: Common stock, the class subject to removal from listing and registration
  • Exchange filing the notice: Nasdaq Stock Market LLC, under Commission File Number 001-35060
  • Rule provision cited: 17 CFR 240.12d2-2(b), indicating the exchange acted pursuant to its own rules to strike the securities from listing
  • Signed by: Tara Petta, AVP, on behalf of Nasdaq Stock Market LLC, dated November 17, 2026

Nasdaq Initiates Delisting of Pacira BioSciences Common Stock

According to the filing, Nasdaq Stock Market LLC submitted a Form 25 to the SEC on November 17, 2026, formally notifying regulators of its intent to remove Pacira BioSciences, Inc. common stock from listing and registration on the exchange. The filing identifies the issuer by its Commission File Number 001-35060 and lists the company's principal executive offices at 5 Sylvan Way, Suite 125, Parsippany, New Jersey 07054.

The form indicates the exchange relied upon 17 CFR 240.12d2-2(b) as the governing rule provision. Under that provision, the filing states that "the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange." The filing does not invoke the voluntary withdrawal provision under 17 CFR 240.12d2-2(c), which would apply if the issuer itself had initiated the withdrawal.

The filing was signed by Tara Petta, identified as AVP, certifying on behalf of Nasdaq Stock Market LLC that the exchange "has reasonable grounds to believe that it meets all of the requirements for filing the Form 25." No reason for the delisting action is stated in the filing itself, and no financial figures or operational disclosures are included.

What Was Disclosed

Nasdaq Stock Market LLC filed a Form 25 to remove Pacira BioSciences, Inc. common stock from listing and registration, citing 17 CFR 240.12d2-2(b). The filing was dated November 17, 2026, and signed by Tara Petta, AVP.